Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase IIa/b study of DDY391 in Sjögren's syndrome
CTR20263088Phase 2Active
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DDY391 in Sjögren's syndrome, sponsored by Novartis. Started Sep 2026; status: active.
02
Drugs
DDY391
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on CTR20263088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263088.